MP0712 shows specific tumor uptake in compassionate care use images.

Molecular Partners has announced new data on MP0712, its lead Radio-DARPin targeting DLL3. The data shows specific uptake in primary tumors and metastatic lesions through rapid internalization and replenishment of DLL3. A Phase 1 IND for MP0712 has been filed, with clinical trial initiation expected before end-2025 in the US and initial data expected in 2026.